SEC Form DEF 14A filed by Amarin Corporation plc
$AMRN
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/20/2023 | Underweight | JP Morgan | |
| 10/25/2023 | $3.00 → $1.00 | Buy → Hold | Jefferies |
| 1/6/2023 | $1.30 → $3.00 | Hold → Buy | Jefferies |
| 5/6/2022 | Neutral → Underweight | JP Morgan | |
| 5/5/2022 | $10.00 → $3.00 | Outperform → Mkt Perform | SVB Leerink |
| 5/5/2022 | $10.00 → $3.00 | Buy → Neutral | H.C. Wainwright |
| 5/4/2022 | Outperform → Market Perform | Northland Capital | |
| 2/16/2022 | $11.00 → $10.00 | Outperform | SVB Leerink |
-- First Quarter 2025 Performance Reflects Contribution from Multiple Revenue Streams Across Geographies, Efforts to Support Strong Balance Sheet and Continued Strategic Execution to Maximize Global Value of VASCEPA®/VAZKEPA® -- -- Nasdaq Listing Compliance Regained Following Completed 1-For-20 ADS Ratio Change -- -- Company to Host Conference Call Today at 8:00 a.m. EDT -- DUBLIN and BRIDGEWATER, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today announced financial results for the first quarter of 2025. "As we begin 2025, our first quarter operational and financial performance reflects continued steady execution against our strategy to maximize the glo
-- Nasdaq Compliance Follows ADS Ratio Change to Secure Company's Public Listing -- -- Amarin Remains Focused on Maximizing the Global Value of VASCEPA/VAZKEPA – DUBLIN and BRIDGEWATER, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced it has regained compliance with the Nasdaq Stock Market ("Nasdaq") continued listing standard for minimum share price under Rule 5550(a)(2) of the Nasdaq Listing Qualifications. On April 29, 2025, the Company received confirmation from the Listing Qualifications Department of Nasdaq that as of April 28, 2025 the Company's common stock had maintained an average closing share price of at least $1.00 over th
DUBLIN and BRIDGEWATER, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin's senior management team to discuss its first quarter 2025 results followed by Q&A on Wednesday, May 7th, 2025, at 8:00 a.m. ET. The conference call with management will follow the release of the Company's first quarter 2025 financial results in the pre-market hours on May 7th. Conference Call and Webcast Information: Access to the live call:Go to the investor relations section of the Company's website at www.amarincorp.comDial in within the United States: 888-506-0062Intern